Annodyne announces the launch of its new division: AIM Rx, a full-service digital health care agency with a concentrated focus on complex specialty markets (e.g., oncology, immunology, virology, neurology, metabolics and orphan designated conditions).
AIM Rx enters into the digital health care marketing scene with vast experience in the biopharma industry and agency experience across all target areas, including professional, payer and consumer. AIM Rx believes it’s this “one-of-a-kind blend of experience” that enables them to deliver fresh solutions that will help drive the future of health care marketing.
AIM Rx will be supported by a board of advisors, known as the Subject Matter Expert (SME) Panel, comprising experienced biopharma executives, marketers, sales professionals, payers and physicians from a variety of therapeutic areas, as well as leaders of nonprofit organizations. The SME Panel will serve to pressure-test the solutions AIM Rx develops for their clients so that they are better prepared to support the industry’s most pressing needs.
“With the U.S. health care landscape rapidly evolving, the biopharma sector needs new innovation from perspectives outside our industry,” said Dr. Michael Castagna, who is known as one of the industry’s change agents. “With Annodyne’s track record of success and AIM Rx’s focus on health care, I am confident they will provide unique viewpoints, capabilities and cutting-edge ideas the biopharma industry isn’t used to.”
AIM Rx has a proven history with traditional digital capabilities; however, their focus is on pre-launch engagement and awareness, payer solutions and customized social engagement platforms. Drawing on their varied experience and guided by the expert advisory panel, AIM Rx will leverage Ziel™, their proprietary audience engagement platform technology, to create fully connected environments of relevant stakeholders.
Ian Houck, director of client relations at AIM Rx said,“Our vision is to integrate and simplify the online patient and provider experiences within complex disease states to identify the right patient, connect them to the right community, and engage them with the right provider to ensure the highest level of care.”
The new agency is made up of four core departments: account services, creative, online marketing/media, and an in-house technology team. “In a landscape of all-too-similar agencies, AIM Rx is truly different,” added Houck. “We have the immediate resources to go head to head with large agencies, but we’re nimble enough to be able to customize our offerings to meet our clients’ specific needs.”
“We’re excited to launch this new division of Annodyne,” said Anthony Campisi, president and CEO of Annodyne, and managing director of AIM Rx. “And we’re anxious to leverage Annodyne’s capabilities to help evolve the digital landscape in the biopharma arena.”